Mirati Therapeutics ( ) - 株価, ニュースと分析BOVESPA:M2RT34

M2RT34 株式概要

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. 詳細

M2RT34 ファンダメンタル分析
スノーフレーク・スコア
評価	3/6
将来の成長	2/6
過去の実績	0/6
財務の健全性	5/6
配当金	0/6

報酬

当社が推定した公正価値より77.7%で取引されている

収益は年間42.24%増加すると予測されています

リスク分析

過去1年間で株主の希薄化が進んだ

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

Mirati Therapeutics, Inc. 競合他社

Blau Farmacêutica

BOVESPA:BLAU3

R$2.6b

Biomm

BOVESPA:BIOM3

R$1.1b

Hypera

BOVESPA:HYPE3

R$12.8b

Bloomage BioTechnology

SHSE:688363

CN¥27.5b

価格と性能

の歴代最高値、変動、値下がりまとめMirati Therapeutics
過去の株価
現在の株価	US$19.46
52週高値	US$21.64
52週安値	US$9.00
ベータ	0.77
11ヶ月の変化	1.35%
3ヶ月変化	4.96%
1年変化	28.96%
33年間の変化	n/a
5年間の変化	n/a
IPOからの変化	-54.84%

Recent updates

株主還元

	M2RT34	BR Biotechs	BR 市場
7D	0.6%	1.2%	0.9%
1Y	29.0%	9.3%	-0.4%

業界別リターン: M2RT34過去 1 年間で9.3 % の収益を上げたBR Biotechs業界を上回りました。

リターン対市場: M2RT34過去 1 年間で-0.4 % の収益を上げたBR市場を上回りました。

価格変動

Is M2RT34's price volatile compared to industry and market?
M2RT34 volatility
M2RT34 Average Weekly Movement	1.7%
Biotechs Industry Average Movement	9.1%
Market Average Movement	4.4%
10% most volatile stocks in BR Market	8.1%
10% least volatile stocks in BR Market	2.3%

安定した株価: M2RT34過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: 過去 1 年間のM2RT34のボラティリティの変化を判断するにはデータが不十分です。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
1995	587	Chuck Baum	www.mirati.com

Mirati Therapeutics, Inc. 基礎のまとめ

Mirati Therapeutics の収益と売上を時価総額と比較するとどうか。
M2RT34 基礎統計学
時価総額	R$20.53b
収益（TTM）	-R$3.62b
売上高(TTM)	R$190.40m

107.8x

P/Sレシオ

-5.7x

PER（株価収益率

M2RT34 は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
M2RT34 損益計算書（TTM）
収益	US$38.19m
売上原価	US$510.48m
売上総利益	-US$472.29m
その他の費用	US$253.59m
収益	-US$725.88m

直近の収益報告

Sep 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-10.35
グロス・マージン	-1,236.66%
純利益率	-1,900.65%
有利子負債／自己資本比率	0%

M2RT34 の長期的なパフォーマンスは？

過去の実績と比較を見る

M2RT34 株式概要

報酬

リスク分析

Mirati Therapeutics, Inc. 競合他社

BOVESPA:BLAU3

R$2.6b

BOVESPA:BIOM3

R$1.1b

BOVESPA:HYPE3

R$12.8b

SHSE:688363

CN¥27.5b

価格と性能

最新ニュース

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

Mirati Therapeutics Announces Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. Submits Marketing Authorization Application to the European Medicines Agency for Investigational adagrasib as a Treatment

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics, Inc. to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib

Mirati Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022

U.S. Food and Drug Administration Accepts New Drug Application for Adagrasib as Treatment of Previously Treated Krasg12c-Mutated Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

株主還元

価格変動

会社概要

Mirati Therapeutics, Inc. 基礎のまとめ

107.8x

-5.7x

収益と収入